UroTech Surgical

Medical Device Company - Preparing FDA 510K Application for Market Introduction. Urology and more specifically Benign Prostatic Hyperplasia (BPH) is a large market opportunity effecting over 500 Million Men globally. BPH surgical technology has not seen any significant advancements in how urologists treat patients suffering from BPH. UroTech Inc. was established to create innovative technologies that will enable urologists to quickly and easily treat BPH surgically while eliminating and or significantly reducing the negative side effects associated with older surgical techniques.